Interferon-alpha (IFN-α) enhances cytotoxicity in healthy volunteers and chronic hepatitis C infection mainly by the perforin pathway

被引:0
作者
Kaser, A [1 ]
Enrich, B [1 ]
Ludwiczek, O [1 ]
Vogel, W [1 ]
Tilg, H [1 ]
机构
[1] Univ Innsbruck Hosp, Dept Med, Div Gastroenterol & Hepatol, A-6020 Innsbruck, Austria
关键词
interferon-alpha; hepatitis C infection; cytotoxicity; perforin; Fas ligand;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cell-mediated cytotoxicity is exerted via perforin and Fas ligand (FasL). We have recently shown that IFN-alpha up-regulates Fast expression in T cells isolated from healthy volunteers and augments activation-induced T cell death. Since the Fas/FasL system is implicated in the pathogenesis of hepatic failure and both molecules have been shown to be up-regulated in hepatitis C virus (HCV) infection, we studied whether cytotoxicity via the Fast system is enhanced by IFN-alpha and therefore could contribute to hepatic injury. We investigated Fast and perforin expression in peripheral blood mononuclear cells (PBMC) derived from HCV+ donors by Northern analysis and soluble Fast synthesis by ELISA. Natural killer (NK) cell and cytotoxic T lymphocyte (CTL) cytotoxicity was studied by Cr-51-release assays. IFN-alpha up-regulates Fast mRNA and protein synthesis in mitogen-activated PBMC of HCV+ individuals, as previously found in healthy subjects. Stimulation with IFN-alpha increases perforin mRNA levels in PBMC. In NK cytotoxicity assays, the enhancement of cytotoxicity by IFN-alpha is mainly due to the perforin pathway, while the Fast pathway plays only a minor role. In CTL cytotoxicity experiments neither the Fast nor the perforin pathway is further enhanced by IFN-alpha. Our data suggest that upregulation of perforin by IFN-alpha results in elevated cytotoxicity, suggesting that IFN-alpha might support elimination of virally infected cells via this pathway. In contrast, the major effect of IFN-alpha on the Fas/FasL system might be the enhanced elimination of activated T cells as a means of finally limiting a T cell response.
引用
收藏
页码:71 / 77
页数:7
相关论文
共 50 条
  • [31] Delayed gastric emptying during interferon-alpha therapy in patients with chronic hepatitis C: Relief by cisapride
    Nishibayashi, H
    Kanayama, S
    Shinomura, Y
    Kawata, S
    Matsuzawa, Y
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1997, 32 (06) : 547 - 551
  • [32] Long-term efficacy of interferon-alpha and ursodeoxycholic acid in treatment of chronic type C hepatitis
    Senturk, H
    Uzunalimoglu, O
    Batur, Y
    Simsek, I
    Mert, A
    Ozbay, G
    Cetinkaya, H
    Ersoz, G
    Tabak, F
    Akbaylar, H
    Akdogan, M
    Dokmeci, A
    Sonsuz, A
    Ozenirler, S
    Erden, E
    Tozum, N
    DIGESTIVE DISEASES AND SCIENCES, 1997, 42 (07) : 1438 - 1444
  • [33] Takotsubo cardiomyopathy and transient thyrotoxicosis during combination therapy with interferon-alpha and ribavirin for chronic hepatitis C
    Carmen Sorina Martin
    Luminita Nicoleta Ionescu
    Carmen Gabriela Barbu
    Anca Elena Sirbu
    Ioana Maria Lambrescu
    Ioana Smarandita Lacau
    Doina Ruxandra Dimulescu
    Simona Vasilica Fica
    BMC Endocrine Disorders, 14
  • [34] Takotsubo cardiomyopathy and transient thyrotoxicosis during combination therapy with interferon-alpha and ribavirin for chronic hepatitis C
    Martin, Carmen Sorina
    Ionescu, Luminita Nicoleta
    Barbu, Carmen Gabriela
    Sirbu, Anca Elena
    Lambrescu, Ioana Maria
    Lacau, Ioana Smarandita
    Dimulescu, Doina Ruxandra
    Fica, Simona Vasilica
    BMC ENDOCRINE DISORDERS, 2014, 14
  • [35] Kinetics of serum soluble tumour necrosis factor receptor (TNF-R) type-I and type-II after a single interferon-alpha (IFN-α) injection in chronic hepatitis C
    Fabris, C
    Del Forno, M
    Falleti, E
    Toniutto, P
    Pirisi, M
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1999, 117 (03) : 556 - 560
  • [36] SERUM HYALURONATE LEVELS PREDICT RESPONSIVENESS TO INTERFERON-ALPHA THERAPY IN PATIENTS WITH CHRONIC HEPATITIS-C
    MATSUNAGA, T
    KOJIMA, J
    INOUE, A
    MATSUMIYA, K
    CLINICA CHIMICA ACTA, 1994, 229 (1-2) : 191 - 195
  • [37] Immunological response in chronic hepatitis C virus infection during interferon alpha therapy
    Panasiuk, A
    Prokopowicz, D
    Zak, J
    HEPATO-GASTROENTEROLOGY, 2004, 51 (58) : 1088 - 1092
  • [38] Decline in haemoglobin A1c values in diabetic patients receiving interferon-alpha and ribavirin for chronic hepatitis C
    Greenberg, P. D.
    Rosman, A. S.
    Eldeiry, L. S.
    Naqvi, Z.
    Brau, N.
    JOURNAL OF VIRAL HEPATITIS, 2006, 13 (09) : 613 - 617
  • [39] Pilot study of ofloxacin and interferon-alpha combination therapy for chronic hepatitis C without sustained response to initial interferon administration
    Komatsu, M
    Ishii, T
    Ono, T
    Hoshino, T
    Kuramitsu, T
    Goto, T
    Fujii, T
    Toyoshima, I
    Chiba, M
    Masamune, O
    CANADIAN JOURNAL OF GASTROENTEROLOGY, 1997, 11 (06): : 507 - 511
  • [40] A ROLE FOR CHRONIC HEPATITIS-C VIRUS-INFECTION IN A PATIENT WITH CUTANEOUS VASCULITIS, CRYOGLOBULINEMIA, AND CHRONIC LIVER-DISEASE - EFFECTIVE THERAPY WITH INTERFERON-ALPHA
    SCHIRREN, CA
    ZACHOVAL, R
    SCHIRREN, CG
    GERBES, AL
    PAPE, GR
    DIGESTIVE DISEASES AND SCIENCES, 1995, 40 (06) : 1221 - 1225